Science News
from research organizations

Celecoxib Does Not Prevent Cancer In Barrett's Esophagus Patients

Date:
April 6, 2007
Source:
Journal of the National Cancer Institute
Summary:
Celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), did not prevent cancer in patients with Barrett's esophagus in a placebo-controlled study, according to new research published in the April 4 Journal of the National Cancer Institute.
Share:
       
FULL STORY

Celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), did not prevent cancer in patients with Barrett’s esophagus in a placebo-controlled study, according to new research published in the April 4 Journal of the National Cancer Institute.

The incidence of Barrett’s esophagus—a precancerous change in the lining of the esophagus that increases the risk of developing esophageal cancer—is on the rise in the United States. Previous studies have suggested that aspirin and other NSAIDs might decrease the risk of esophageal cancer.

In a randomized controlled phase II trial, Elisabeth I. Health, M.D., of the Barbara Ann Karmanos Cancer Institute in Detroit, and colleagues randomly assigned 100 Barrett’s esophagus patients to take 200 mg of celecoxib or a placebo twice a day. After 48 weeks of treatment, there was no difference in the progression to esophageal cancer between the two groups.

"The lack of secondary chemoprevention with celecoxib in patients with Barrett’s [esophagus] was disappointing. However, [the trial] is one of the few prospective chemoprevention trials in patient’s with Barrett’s [esophagus], and through it, we have gained valuable information about the disease process and the challenges of conducting such a study," the authors write.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute.


Story Source:

The above post is reprinted from materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Celecoxib Does Not Prevent Cancer In Barrett's Esophagus Patients." ScienceDaily. ScienceDaily, 6 April 2007. <www.sciencedaily.com/releases/2007/04/070403225314.htm>.
Journal of the National Cancer Institute. (2007, April 6). Celecoxib Does Not Prevent Cancer In Barrett's Esophagus Patients. ScienceDaily. Retrieved August 3, 2015 from www.sciencedaily.com/releases/2007/04/070403225314.htm
Journal of the National Cancer Institute. "Celecoxib Does Not Prevent Cancer In Barrett's Esophagus Patients." ScienceDaily. www.sciencedaily.com/releases/2007/04/070403225314.htm (accessed August 3, 2015).

Share This Page: